The Biopharmaceutical Processing Equipment and Consumables Market is expected to grow at a CAGR of 10.3% from 2022 to 2029 to reach $70.84 billion by 2029. Biopharmaceutical processing involves the study of discovery, development, and processing of complex medicines using living cells and organisms. Biopharmaceuticals include vaccines, whole blood and blood components, gene therapies, recombinant therapeutic proteins, gene therapies, and somatic cells.
Biopharmaceutical processing uses equipment, such as filtration systems, chromatography equipment and consumables, bioreactors, cell culture systems, mixing systems, bioprocessing containers, sterilizers, centrifuges, incubators, biosafety cabinets, and other equipment like membrane adsorbers, cell disruption reagents, pipettes, syringes, vials, closures, tubing, connectors, and sensors for commercial and research-based bioproduction.
The biopharmaceutical processing equipment and consumables market is growing on account of global initiatives supporting the adoption of biopharmaceuticals, capacity expansions of biopharmaceutical plants, and growing adoption of single-use bioprocessing equipment and consumables. Further, the shift towards bioprocessing 4.0, emerging economies, and rising adoption of personalized medicines offer opportunities for market growth.
COVID-19 Impact Assessment
The COVID-19 pandemic impacted the biopharmaceutical processing equipment and consumables market, both positively and negatively. The biopharma industry adopted improved strategies to tackle the pandemic, prepare for future pandemics, and minimize supply disruptions. The industry is witnessing partnerships and collaborations focused on accelerating R&D and implementing flexible, rapid, and modular production processes to speed up the products’ time to market. Such factors are likely to accelerate the adoption of biopharmaceutical processing equipment.
China and India, one of the emerging biopharma hubs, lockdowns resulted in disrupted raw material supply chains and posed operational and staffing challenges. However, with relaxations in the national lockdowns, public authorities, policymakers, and pharmaceutical manufacturers paced the process of COVID-19 vaccine development and production. Thus, with the growing number of vaccine and therapeutic candidates for COVID-19 in the clinical pipeline, the demand for biopharmaceutical processing equipment is expected to rise.
Thus, apart from the negative impact due to temporary supply chain and manufacturing disruptions due to nationwide lockdowns and delayed response from the regulatory authorities, the overall impact of the pandemic has been positive on the market.
Click here to: Get Sample Pages of this Report
Growing Adoption of Single-use Bioprocessing Equipment for Commercial Production is Driving the Market Growth
So far, the biopharmaceutical processing industry has been dominated by stainless-steel/reusable equipment. Most biopharmaceutical manufacturing plants have fixed stainless-steel bioreactors, mixers, and bioprocessing vessels. However, in the last few years, the trend has been shifting towards the adoption of single-use/disposable equipment. This is attributed to various advantages these equipment has over conventional stainless-steel equipment such as reduced manufacturing costs (by eliminating cleaning and cleaning validation steps).
Besides reducing the time and labor required, single-use technologies also help reduce capital costs and energy consumption, improving efficiency. Although single-use systems generate waste from incinerating and discarding plastic materials, they still leave a smaller carbon footprint than permanent steel systems. The carbon dioxide released after generating steam for water for injection (WFI) cleaning and the steam-in-place sterilization of stainless-steel vessels, piping, and other hardware are far more than the carbon dioxide produced from the manufacture and disposal plastic single-use systems. Thus, the usage of WFI, steam, and cleaning agents is reduced significantly by incorporating single-use platforms.
Single-use systems (SUS) are largely used at a clinical scale for over 80% of bioprocessing operations. However, biomanufacturers and contract manufacturing organizations (CMOs) are expected to exhibit greater adoption of such systems as pipeline SUS products are increasingly approved and entered commercial production. Because most SUS are already being used in scale-up/clinical production and are about to reach saturation, the future trend will be - a greater use of these devices in commercial production where traditional multi-use stainless-steel systems still exist have a dominance.
Growing Focus on Continuous Bioprocessing is the Trend Prevailing the Market
For a long time, batch/fed-batch mode has dominated the manufacturing of biopharmaceuticals. However, it has some limitations - it requires additional instruments for feedback control and is costly operation costs compared to continuous bioprocessing. In the continuous bioprocessing, the process is performed at a single location without interruption, as there is a continuous flow of raw materials in and out of the bioreactor with the processing of the intermediate or final product - in contrast to batch culture - in which specific quantity of product is produced in a discrete volume during the same cycle of manufacture, and the process is frequently segmented into many individual steps that are often performed at separate facilities.
Moreover, the continuous processing leads to the production of the quality end product with no variation and offers steady-state operation, reduced equipment size, streamlined process flow, and reduced capital costs.
Due to the growing demand for innovative and complex therapies and the growing competition in the biopharmaceuticals market, biopharmaceutical manufacturers are reconsidering manufacturing methods (shifting from batch to continuous manufacturing). Although batch manufacturing is the most preferred method, continuous manufacturing is increasingly accepted in the pharmaceutical industry due to its commercial advantages.
Key Findings in the Global Biopharmaceutical Processing Equipment and Consumables Market Study:
Based on product type, the filtration segment is estimated to generate a large proportion of revenue in 2022
The process of filtration is the basic requisite across all stages in bioproduction. Filtration is commonly used in biopharmaceutical processing for separating components. It is used in various downstream operations, such as clarification, filtration of intermediates, critical final filling applications, or upstream processing for sterilizing-grade filtration of cell culture media. The highest revenue share is attributed to the recurring use of filtration at every step in bioprocessing and technological advancements in filtration technologies.
By application, the commercial bioproduction segment is projected to grow at the highest CAGR over the forecast period
Growing initiatives supporting the adoption of biopharmaceuticals, rising biopharmaceutical manufacturing outsourcing, and accelerated developments in personalized therapies are likely to enhance the demand for bioprocessing equipment and consumables for the commercial bioproduction of monoclonal antibodies (mAbs), vaccines, gene therapies, and recombinant protein-based therapies.
Based on end user, the pharmaceutical and biopharmaceutical companies segment to account for the largest share of the market in 2022
Capacity expansion of biopharmaceutical manufacturers and the growing adoption of the biopharmaceutical processing equipment for bioproduction is the key factor attributing to the largest market share. The development and manufacturing of biopharmaceuticals are gaining pace. Biopharmaceuticals account for nearly 25% of the pharmaceutical market. Thus, growing manufacturing by biopharmaceutical companies has driven the demand for biopharmaceutical processing equipment and consumables.
Asia-Pacific: Fastest growing regional market
The growth in this market is attributed to the factors like growing outsourcing of biopharmaceutical manufacturing in the countries like China, India, Singapore, and South Korea; rising biotechnology spending by public authorities; and growing initiatives supporting the adoption of biopharmaceuticals. Further, growing awareness of personalized medicines and the development of biotechnology incubators is also accelerating the market growth.
Key Players
The report includes a competitive landscape based on extensive assessment of the key strategic developments that led market participants to adopt over the past three years. The key players profiled in the global biopharmaceutical processing equipment and consumables market report are 3M Company (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Danaher Corporation (U.S.), Agilent Technologies, Inc (U.S.), Repligen Corporation (U.S.), Sartorius AG (Germany), Merck KGaA (Germany), Eppendorf AG (Germany), and Solaris Biotechnology Srl (Italy)
Scope of the Report:
Biopharmaceutical Processing Equipment and Consumables Market, by Product Type
- Filtration Systems
- Chromatography Equipment and Consumables
- Bioreactors
- Reusable Bioreactors
- Disposable/Single-use Bioreactors
- Cell Culture Products
- Cell Culture Media
- Cell Culture Media, by Physical Form
- Dry Powder Media
- Liquid Media
- Cell Culture Media, by Type
- Off-the-Shelf Media
- Custom Media
- Cell Culture Media, by Source
- Chemically Defined Media
- Natural Media
- Reagents and Supplements
- Cell and Cell Lines
- Serum
- Mixing Systems
- Bioprocessing Containers
- Sterilizers
- Centrifuges
- Incubators
- Shakers
- Biosafety Cabinets
- Other Equipment and Consumables
- Service
(Note: Other equipment and consumables include membrane adsorbers, cell disruption reagents, pipettes, syringes, vials, closures, tubing, connectors, and sensors)
Biopharmaceutical Processing Equipment and Consumables Market, by Application
- Commercial Bioproduction
- Vaccine Manufacturing
- mAb Production
- Recombinant Protein Production
- Cell and Gene Therapy Production
- Research Bioproduction
Biopharmaceutical Processing Equipment and Consumables Market, by End User
- Pharmaceutical and Biopharmaceutical Companies
- Contract Development and Manufacturing Organizations (CDMOs)
- Academia and Research Institutes
Biopharmaceutical Processing Equipment and Consumables Market, by Geography
- North America
- Europe
- Germany
- U. K.
- France
- Italy
- Spain
- Switzerland
- Denmark
- Ireland
- Belgium
- Rest of Europe (RoE)
- Asia-Pacific (APAC)
- China
- Japan
- India
- South Korea
- Rest of APAC (RoAPAC)
- Latin America
- Middle East & Africa
Key questions answered in the report: